{"hands_on_practices": [{"introduction": "A core principle in pharmacogenomics is that genetic variations in a drug target can alter binding affinity, leading to differential drug response. This exercise [@problem_id:5042183] demonstrates how to quantify this change using fundamental thermodynamic principles. By applying the relationship between the standard Gibbs free energy of binding ($\\Delta G^{\\circ}$) and the equilibrium dissociation constant ($K_D$), you will calculate how a clinically relevant mutation in the *EGFR* protein impacts inhibitor binding, providing a quantitative molecular basis for altered drug efficacy.", "problem": "A translational pharmacogenomics study investigates how the leucine-to-arginine substitution at position $858$ in Epidermal Growth Factor Receptor (EGFR) (L858R) affects the binding of a clinical small-molecule inhibitor. Under identical buffer conditions at the standard state of $1 \\ \\mathrm{M}$ and at physiological temperature $T = 310 \\ \\mathrm{K}$, isothermal titration calorimetry yields the following standard binding Gibbs free energies for the inhibitor: for wild-type *EGFR*, $\\Delta G^{\\circ}_{\\mathrm{WT}} = -35.2 \\ \\mathrm{kJ \\ mol^{-1}}$, and for EGFR-L858R, $\\Delta G^{\\circ}_{\\mathrm{L858R}} = -41.3 \\ \\mathrm{kJ \\ mol^{-1}}$. Using the statistical thermodynamic relation between standard Gibbs free energy and the equilibrium association constant, together with the definition of the equilibrium dissociation constant, derive an expression for the fold-change in the equilibrium dissociation constant, $K_{D,\\mathrm{L858R}} / K_{D,\\mathrm{WT}}$, in terms of the difference in standard Gibbs free energy of binding, $\\Delta \\Delta G^{\\circ} = \\Delta G^{\\circ}_{\\mathrm{L858R}} - \\Delta G^{\\circ}_{\\mathrm{WT}}$. Then compute $\\Delta \\Delta G^{\\circ}$ and the fold-change $K_{D,\\mathrm{L858R}} / K_{D,\\mathrm{WT}}$. Use the molar gas constant $R = 8.314 \\ \\mathrm{J \\ mol^{-1} \\ K^{-1}}$. Report $\\Delta \\Delta G^{\\circ}$ in $\\mathrm{kJ \\ mol^{-1}}$ and report the fold-change as a pure decimal factor. Round each to three significant figures.", "solution": "The first step is to derive the relationship between the fold-change in the equilibrium dissociation constant ($K_D$) and the change in the standard Gibbs free energy of binding ($\\Delta \\Delta G^{\\circ}$).\n\nThe fundamental relationship in statistical thermodynamics connecting the standard Gibbs free energy of a reaction, $\\Delta G^{\\circ}$, and its equilibrium constant, $K_{eq}$, is given by:\n$$\n\\Delta G^{\\circ} = -RT \\ln K_{eq}\n$$\nwhere $R$ is the molar gas constant and $T$ is the absolute temperature.\n\nFor a bimolecular binding event, such as an inhibitor binding to an enzyme, the reaction is:\n$$\n\\text{Enzyme} + \\text{Inhibitor} \\rightleftharpoons \\text{Enzyme-Inhibitor Complex}\n$$\nThe equilibrium constant for this association reaction is the association constant, $K_A$. Thus, the standard Gibbs free energy of binding is related to $K_A$ by:\n$$\n\\Delta G^{\\circ} = -RT \\ln K_A\n$$\nThe equilibrium dissociation constant, $K_D$, is the reciprocal of the association constant, $K_A$:\n$$\nK_D = \\frac{1}{K_A}\n$$\nSubstituting $K_A = 1/K_D$ into the Gibbs free energy equation yields:\n$$\n\\Delta G^{\\circ} = -RT \\ln \\left(\\frac{1}{K_D}\\right) = -RT (-\\ln K_D) = RT \\ln K_D\n$$\nThis equation applies to both the wild-type (WT) EGFR and the mutant (L858R) EGFR. For each case, we can write:\n$$\n\\Delta G^{\\circ}_{\\mathrm{WT}} = RT \\ln K_{D, \\mathrm{WT}}\n$$\n$$\n\\Delta G^{\\circ}_{\\mathrm{L858R}} = RT \\ln K_{D, \\mathrm{L858R}}\n$$\nThe problem defines the difference in the standard Gibbs free energy of binding as $\\Delta \\Delta G^{\\circ} = \\Delta G^{\\circ}_{\\mathrm{L858R}} - \\Delta G^{\\circ}_{\\mathrm{WT}}$. We can substitute the expressions above into this definition:\n$$\n\\Delta \\Delta G^{\\circ} = (RT \\ln K_{D, \\mathrm{L858R}}) - (RT \\ln K_{D, \\mathrm{WT}})\n$$\nFactoring out the term $RT$ and using the logarithmic identity $\\ln a - \\ln b = \\ln(a/b)$, we get:\n$$\n\\Delta \\Delta G^{\\circ} = RT (\\ln K_{D, \\mathrm{L858R}} - \\ln K_{D, \\mathrm{WT}}) = RT \\ln\\left(\\frac{K_{D, \\mathrm{L858R}}}{K_{D, \\mathrm{WT}}}\\right)\n$$\nTo derive the expression for the fold-change in the dissociation constant, $K_{D,\\mathrm{L858R}} / K_{D,\\mathrm{WT}}$, we rearrange the equation:\n$$\n\\frac{\\Delta \\Delta G^{\\circ}}{RT} = \\ln\\left(\\frac{K_{D, \\mathrm{L858R}}}{K_{D, \\mathrm{WT}}}\\right)\n$$\nExponentiating both sides gives the desired expression:\n$$\n\\frac{K_{D, \\mathrm{L858R}}}{K_{D, \\mathrm{WT}}} = \\exp\\left(\\frac{\\Delta \\Delta G^{\\circ}}{RT}\\right)\n$$\nThis completes the derivation.\n\nThe second step is to compute the numerical values for $\\Delta \\Delta G^{\\circ}$ and the fold-change.\nThe given values are:\n$\\Delta G^{\\circ}_{\\mathrm{WT}} = -35.2 \\ \\mathrm{kJ \\ mol^{-1}}$\n$\\Delta G^{\\circ}_{\\mathrm{L858R}} = -41.3 \\ \\mathrm{kJ \\ mol^{-1}}$\n$T = 310 \\ \\mathrm{K}$\n$R = 8.314 \\ \\mathrm{J \\ mol^{-1} \\ K^{-1}}$\n\nFirst, we calculate $\\Delta \\Delta G^{\\circ}$:\n$$\n\\Delta \\Delta G^{\\circ} = \\Delta G^{\\circ}_{\\mathrm{L858R}} - \\Delta G^{\\circ}_{\\mathrm{WT}} = -41.3 \\ \\mathrm{kJ \\ mol^{-1}} - (-35.2 \\ \\mathrm{kJ \\ mol^{-1}})\n$$\n$$\n\\Delta \\Delta G^{\\circ} = -41.3 + 35.2 \\ \\mathrm{kJ \\ mol^{-1}} = -6.1 \\ \\mathrm{kJ \\ mol^{-1}}\n$$\nThe problem requires this value to be reported to three significant figures, so we write:\n$$\n\\Delta \\Delta G^{\\circ} = -6.10 \\ \\mathrm{kJ \\ mol^{-1}}\n$$\nNext, we calculate the fold-change in $K_D$. We must ensure consistent units for energy. We convert $\\Delta \\Delta G^{\\circ}$ from $\\mathrm{kJ \\ mol^{-1}}$ to $\\mathrm{J \\ mol^{-1}}$:\n$$\n\\Delta \\Delta G^{\\circ} = -6.10 \\ \\mathrm{kJ \\ mol^{-1}} = -6.10 \\times 10^3 \\ \\mathrm{J \\ mol^{-1}}\n$$\nNow we can compute the argument of the exponential:\n$$\n\\frac{\\Delta \\Delta G^{\\circ}}{RT} = \\frac{-6.10 \\times 10^3 \\ \\mathrm{J \\ mol^{-1}}}{(8.314 \\ \\mathrm{J \\ mol^{-1} \\ K^{-1}}) \\times (310 \\ \\mathrm{K})} = \\frac{-6100}{2577.34} \\approx -2.36670\n$$\nThe fold-change is the exponential of this value:\n$$\n\\frac{K_{D, \\mathrm{L858R}}}{K_{D, \\mathrm{WT}}} = \\exp(-2.36670) \\approx 0.09379\n$$\nRounding this result to three significant figures gives:\n$$\n\\frac{K_{D, \\mathrm{L858R}}}{K_{D, \\mathrm{WT}}} \\approx 0.0938\n$$\nThe negative value of $\\Delta \\Delta G^{\\circ}$ indicates that the mutation makes binding more favorable (energetically stabilizing), which is consistent with a decrease in the dissociation constant ($K_{D, \\mathrm{L858R}} < K_{D, \\mathrm{WT}}$), signifying stronger binding.\n\nThe two computed values, rounded to three significant figures as required, are $\\Delta \\Delta G^{\\circ} = -6.10 \\ \\mathrm{kJ \\ mol^{-1}}$ and the fold-change is $0.0938$.", "answer": "$$\n\\boxed{\\begin{pmatrix} -6.10 & 0.0938 \\end{pmatrix}}\n$$", "id": "5042183"}, {"introduction": "Understanding the pharmacogenomics of a drug target involves not only whether a drug works but also how quickly its effects manifest in a patient. This practice [@problem_id:5042222] explores the temporal dynamics of warfarin, an anticoagulant that inhibits the *VKORC1* enzyme. You will use the known plasma half-lives of downstream clotting factors to predict the time course of change in the International Normalized Ratio (INR), illustrating how the turnover kinetics of relevant proteins govern the clinical pharmacodynamic response.", "problem": "A patient with nonvalvular atrial fibrillation is managed with warfarin, which inhibits the Vitamin K epoxide reductase complex subunit 1 (VKORC1), thereby reducing gamma-carboxylation of the vitamin K–dependent clotting factors II, VII, IX, and X. The patient’s genotype is `VKORC1 -1639 G>A` homozygous A/A, known to confer increased pharmacodynamic sensitivity to warfarin at the target (lower dose requirement). After a period of stability at an International Normalized Ratio (INR) of $2.5$ (International Normalized Ratio standardizes Prothrombin Time (PT), which reflects the extrinsic and common coagulation pathways), the clinician increases the warfarin dose by $25\\%$ to achieve a higher intensity of anticoagulation because of a new thrombotic risk.\n\nAssume the following well-established plasma half-lives under steady-state physiology: factor II $(60\\ \\mathrm{h})$, factor VII $(6\\ \\mathrm{h})$, factor IX $(24\\ \\mathrm{h})$, and factor X $(40\\ \\mathrm{h})$. The dosing change instantaneously increases VKORC1 inhibition, thus reducing the synthesis rate of the gamma-carboxylated (functional) forms of these factors. Considering protein turnover and the pathway specificity of PT/INR, which option best predicts the temporal sequence and qualitative pattern of INR changes over the first several days following this dosing change?\n\nA. The earliest measurable INR rise occurs within $6$–$12\\ \\mathrm{h}$, driven predominantly by depletion of factor VII $(t_{1/2}=6\\ \\mathrm{h})$; additional increases accrue over $24$–$72\\ \\mathrm{h}$ as factor X and then factor II decline, with approximate stabilization near a new steady state after $5$–$7$ days; changes in factor IX have minimal direct effect on PT/INR.\n\nB. INR remains essentially unchanged for approximately $60\\ \\mathrm{h}$ until factor II declines, because factor VII contributes little to PT; after factor II falls, INR rapidly reaches a new steady state within $24\\ \\mathrm{h}$.\n\nC. INR initially falls for $12\\ \\mathrm{h}$ due to accelerated loss of protein C and protein S before rising as factor IX declines at $24\\ \\mathrm{h}$; the maximal INR rise occurs by $24\\ \\mathrm{h}$.\n\nD. Because *VKORC1* A/A accelerates warfarin action at the target, all vitamin K–dependent factors decline simultaneously, producing a uniform INR rise peaking within $12\\ \\mathrm{h}$ and fully stabilizing by $24\\ \\mathrm{h}$.", "solution": "This problem requires an understanding of warfarin's pharmacodynamics, specifically how it affects the coagulation cascade over time.\n\n1.  **Identify the Measurement and Relevant Pathway:** The clinical effect is measured by the International Normalized Ratio (INR), which is derived from the Prothrombin Time (PT). The PT test specifically assesses the function of the **extrinsic pathway** (initiated by Factor VII) and the **common pathway** (involving Factors X, V, II, and I). Factors V and I are not vitamin K-dependent. Therefore, the INR is sensitive to the levels of functional, carboxylated Factors VII, X, and II. Factor IX is part of the intrinsic pathway (measured by the aPTT) and does not directly influence the INR.\n\n2.  **Analyze the Drug's Effect on Protein Synthesis:** Warfarin inhibits the VKORC1 enzyme, which is necessary for recycling vitamin K. This action blocks the gamma-carboxylation and thus the synthesis of *new* functional clotting factors II, VII, IX, and X. When the warfarin dose is increased, this inhibition becomes more profound, effectively shutting down the production of these functional proteins.\n\n3.  **Apply Protein Turnover Kinetics:** The existing pool of functional clotting factors in the plasma is not immediately affected. These proteins will be cleared from circulation at a rate determined by their individual biological half-lives ($t_{1/2}$). The concentration of each factor will decline exponentially. The INR will begin to rise as the concentration of the factor with the shortest half-life drops to a critically low level.\n\n4.  **Predict the Temporal Sequence based on Half-Lives:**\n    *   **Factor VII:** Has the shortest half-life ($t_{1/2} = 6\\ \\mathrm{h}$). Its concentration will decrease most rapidly. A significant drop will occur within 6-12 hours ($1-2$ half-lives), causing the **earliest measurable increase in INR**.\n    *   **Factor IX:** Has a half-life of $24\\ \\mathrm{h}$, but is irrelevant to the INR.\n    *   **Factor X:** Has a longer half-life ($t_{1/2} = 40\\ \\mathrm{h}$). Its decline will contribute to the INR rise after the initial effect of Factor VII depletion.\n    *   **Factor II (Prothrombin):** Has the longest half-life ($t_{1/2} = 60\\ \\mathrm{h}$). Its depletion will be the slowest, contributing to a continued, gradual increase in INR over several days. The time to reach a new, stable, higher INR is determined by this rate-limiting factor, typically taking $4-5$ of its half-lives (i.e., $240-300$ hours, or over 10 days). Therefore, \"approximate stabilization\" after 5-7 days is a reasonable description of the process approaching the new steady state.\n\n5.  **Evaluate the Options:**\n    *   **A:** This option correctly identifies that the earliest INR rise is due to Factor VII depletion within 6-12 hours. It accurately describes the subsequent, slower rise due to Factor X and II depletion. It correctly notes that the approach to a new steady state takes several days and that Factor IX has a minimal effect. This aligns perfectly with our analysis.\n    *   **B:** This option is incorrect. It wrongly claims Factor VII contributes little to PT and that the INR is stable for 60 hours. PT is highly sensitive to Factor VII levels.\n    *   **C:** This option is incorrect. A decrease in the natural anticoagulants Protein C and S (which also have short half-lives) can cause a transient hypercoagulable state at the *initiation* of therapy, but it does not cause the INR to *fall*. The INR measures procoagulant activity, so less activity means a higher INR. Furthermore, it incorrectly cites Factor IX as a driver of the INR rise.\n    *   **D:** This option is incorrect. It mistakenly claims that the genotype \"accelerates\" the action and that all factors decline simultaneously. The genotype increases *sensitivity* to the drug, but the temporal decay of existing proteins is dictated by their half-lives, which are very different. The full effect is not reached in 24 hours due to the long half-life of Factor II.\n\nTherefore, option A provides the most accurate description of the pharmacodynamic time course.", "answer": "$$\\boxed{A}$$", "id": "5042222"}, {"introduction": "A primary goal of translational pharmacogenomics is to build quantitative models that predict drug response from an individual's genetic profile. This computational exercise [@problem_id:5042251] guides you through the process of estimating genotype-specific pharmacodynamic parameters directly from clinical data. You will fit a saturable $E_{\\max}$ model, which is mechanistically derived from receptor occupancy theory, to dose-response data to determine how a genetic variant impacts a drug's potency ($EC_{50}$) and maximal effect ($E_{\\max}$).", "problem": "You are given paired measurements of heart rate before and after dosing with a beta-adrenergic receptor antagonist (beta-blocker) in subjects stratified by genotype. Assume the effect of the drug on heart rate reduction adheres to receptor-binding driven pharmacodynamics grounded in the Law of Mass Action and receptor occupancy, leading to a saturable relationship between dose and effect. Each genotype is expected to have its own maximum achievable effect and potency, represented by two parameters: the maximum heart rate reduction $E_{\\max}$ (in beats per minute) and the dose achieving half the maximum effect $EC_{50}$ (in milligrams). The effect is defined as the change from baseline heart rate ($\\Delta HR = HR_{\\text{baseline}} - HR_{\\text{post}}$), measured in beats per minute. You must estimate $E_{\\max}$ and $EC_{50}$ for each genotype by fitting a mechanistically derived, saturable dose-effect model to the observed $\\Delta HR$ across doses. The fitting must be done using non-linear least squares with bound constraints that enforce pharmacological plausibility. All dose values must be treated in milligrams, all heart rate values in beats per minute, and angles are not involved in this task. The final program must produce the estimates rounded to two decimal places, with $E_{\\max}$ reported in beats per minute and $EC_{50}$ in milligrams.\n\nUse the following test suite. Each test case consists of two genotypes, labeled Genotype A and Genotype B. For each genotype, you are provided a dose vector (in milligrams), a baseline heart rate vector (in beats per minute), and a post-dose heart rate vector (in beats per minute). Compute $\\Delta HR$ as $HR_{\\text{baseline}} - HR_{\\text{post}}$ at each observation and fit the mechanistically justified saturable dose-effect model to estimate genotype-specific $E_{\\max}$ and $EC_{50}$. The model should be fitted separately for each genotype. Constrain the parameters to $E_{\\max} \\in [0, 100]$ (in beats per minute) and $EC_{50} \\in [10^{-3}, 200]$ (in milligrams).\n\nTest Case $1$ (moderate doses with clear genotype effect separation):\n- Genotype A:\n  - Dose (mg): $[0, 2, 2, 5, 5, 10, 10, 25, 25]$\n  - Baseline HR (bpm): $[80, 82, 78, 81, 79, 83, 77, 84, 80]$\n  - Post-dose HR (bpm): $[80, 73.729, 69.329, 65.8, 64.5, 63.0, 57.4, 58.7, 55.2]$\n- Genotype B:\n  - Dose (mg): $[0, 2, 2, 5, 5, 10, 10, 25, 25]$\n  - Baseline HR (bpm): $[78, 80, 82, 79, 83, 84, 76, 85, 81]$\n  - Post-dose HR (bpm): $[78, 77.747, 79.447, 74.3, 77.9, 76.2, 68.0, 72.1, 69.0]$\n\nTest Case $2$ (high-dose saturation regime with similar $E_{\\max}$ but different $EC_{50}$):\n- Genotype A:\n  - Dose (mg): $[0, 20, 20, 40, 40, 80, 80]$\n  - Baseline HR (bpm): $[88, 90, 86, 87, 89, 90, 85]$\n  - Post-dose HR (bpm): $[88, 59.765, 55.465, 54.742, 55.942, 56.266, 51.366]$\n- Genotype B:\n  - Dose (mg): $[0, 20, 20, 40, 40, 80, 80]$\n  - Baseline HR (bpm): $[92, 91, 90, 88, 89, 90, 87]$\n  - Post-dose HR (bpm): $[92, 65.9, 65.2, 58.633, 59.833, 58.482, 55.082]$\n\nTest Case $3$ (low-dose regime testing identifiability under shallow curvature):\n- Genotype A:\n  - Dose (mg): $[0, 1, 1, 2, 2, 4, 4, 8, 8]$\n  - Baseline HR (bpm): $[80, 82, 78, 81, 79, 83, 77, 84, 80]$\n  - Post-dose HR (bpm): $[80, 81.61, 77.31, 80.038, 78.238, 81.048, 75.148, 80.752, 76.252]$\n- Genotype B:\n  - Dose (mg): $[0, 1, 1, 2, 2, 4, 4, 8, 8]$\n  - Baseline HR (bpm): $[81, 80, 82, 79, 83, 84, 76, 85, 81]$\n  - Post-dose HR (bpm): $[81, 75.733, 77.833, 72.057, 75.657, 72.889, 65.189, 69.215, 65.715]$\n\nAlgorithmic requirements:\n- Derive the saturable dose-effect relationship from a receptor occupancy framework and fit the $\\Delta HR$ data versus dose to recover genotype-specific $E_{\\max}$ and $EC_{50}$ via non-linear least squares.\n- Use bounded optimization: $E_{\\max} \\in [0, 100]$ and $EC_{50} \\in [10^{-3}, 200]$.\n- The fitting must be performed independently for each genotype within each test case.\n- Report the final estimates rounded to two decimal places, with $E_{\\max}$ in beats per minute and $EC_{50}$ in milligrams.\n\nFinal output format:\nYour program should produce a single line of output containing the results as a comma-separated list enclosed in square brackets. The output must be a list of three sublists, one per test case, each sublist ordered as $[E_{\\max}^{A}, EC_{50}^{A}, E_{\\max}^{B}, EC_{50}^{B}]$ with each value rounded to two decimal places and implicitly in its required unit. For example, the structure must be exactly like $[[x_1, y_1, x_2, y_2],[x_3, y_3, x_4, y_4],[x_5, y_5, x_6, y_6]]$, where all $x_i$ are $E_{\\max}$ values (in beats per minute) and all $y_i$ are $EC_{50}$ values (in milligrams).", "solution": "The problem requires the estimation of pharmacodynamic parameters from dose-response data for different genotypes. This is a standard task in quantitative pharmacology and pharmacogenomics. Before proceeding with the solution, the problem statement is validated.\n\n### Problem Validation\n\n**Step 1: Extract Givens**\n\n*   **Pharmacodynamic Model**: A saturable dose-effect model derived from receptor-binding and the Law of Mass Action.\n*   **Parameters to Estimate**: $E_{\\max}$ (maximum heart rate reduction, in beats per minute) and $EC_{50}$ (dose for half-maximal effect, in milligrams).\n*   **Effect Definition**: $\\Delta HR = HR_{\\text{baseline}} - HR_{\\text{post}}$ (in beats per minute).\n*   **Fitting Method**: Non-linear least squares.\n*   **Parameter Constraints**: $E_{\\max} \\in [0, 100]$ bpm and $EC_{50} \\in [10^{-3}, 200]$ mg.\n*   **Data Structure**: Three test cases are provided, each with data for two genotypes (A and B). Each genotype dataset includes:\n    *   Dose vector (mg)\n    *   Baseline HR vector (bpm)\n    *   Post-dose HR vector (bpm)\n*   **Test Case 1**:\n    *   Genotype A: Dose: $[0, 2, 2, 5, 5, 10, 10, 25, 25]$, Baseline HR: $[80, 82, 78, 81, 79, 83, 77, 84, 80]$, Post-dose HR: $[80, 73.729, 69.329, 65.8, 64.5, 63.0, 57.4, 58.7, 55.2]$\n    *   Genotype B: Dose: $[0, 2, 2, 5, 5, 10, 10, 25, 25]$, Baseline HR: $[78, 80, 82, 79, 83, 84, 76, 85, 81]$, Post-dose HR: $[78, 77.747, 79.447, 74.3, 77.9, 76.2, 68.0, 72.1, 69.0]$\n*   **Test Case 2**:\n    *   Genotype A: Dose: $[0, 20, 20, 40, 40, 80, 80]$, Baseline HR: $[88, 90, 86, 87, 89, 90, 85]$, Post-dose HR: $[88, 59.765, 55.465, 54.742, 55.942, 56.266, 51.366]$\n    *   Genotype B: Dose: $[0, 20, 20, 40, 40, 80, 80]$, Baseline HR: $[92, 91, 90, 88, 89, 90, 87]$, Post-dose HR: $[92, 65.9, 65.2, 58.633, 59.833, 58.482, 55.082]$\n*   **Test Case 3**:\n    *   Genotype A: Dose: $[0, 1, 1, 2, 2, 4, 4, 8, 8]$, Baseline HR: $[80, 82, 78, 81, 79, 83, 77, 84, 80]$, Post-dose HR: $[80, 81.61, 77.31, 80.038, 78.238, 81.048, 75.148, 80.752, 76.252]$\n    *   Genotype B: Dose: $[0, 1, 1, 2, 2, 4, 4, 8, 8]$, Baseline HR: $[81, 80, 82, 79, 83, 84, 76, 85, 81]$, Post-dose HR: $[81, 75.733, 77.833, 72.057, 75.657, 72.889, 65.189, 69.215, 65.715]$\n*   **Output Format**: A list of three sublists, with each sublist containing $[E_{\\max}^{A}, EC_{50}^{A}, E_{\\max}^{B}, EC_{50}^{B}]$ rounded to two decimal places.\n\n**Step 2: Validate Using Extracted Givens**\n\n*   **Scientifically Grounded**: The problem is based on the classical Emax model of pharmacodynamics, which is derived from the Law of Mass Action and receptor occupancy theory. This is a fundamental and well-established principle in pharmacology. All aspects of the problem are scientifically sound.\n*   **Well-Posed**: The problem is to perform a non-linear regression, which is a well-defined mathematical problem. The data, model, and constraints are provided, ensuring that a unique and stable solution can be found.\n*   **Objective**: The problem is described using precise mathematical language and numerical data. The task is objective and free from subjective interpretation.\n*   **Other Flaws**: The problem is self-contained, consistent, and scientifically plausible. It does not violate any of the invalidity criteria.\n\n**Step 3: Verdict and Action**\n\nThe problem is **valid**. A solution will be provided.\n\n### Solution\n\nThe solution involves deriving the appropriate pharmacodynamic model and then using non-linear least squares to fit this model to the provided experimental data for each genotype.\n\n**1. Mechanistic Model Derivation**\n\nThe relationship between drug dose and its pharmacological effect is based on the interaction of the drug with its target receptors. The process can be modeled by the Law of Mass Action. Let $D$ represent the drug, $R$ the free receptor, and $DR$ the drug-receptor complex. The reversible binding is described by the equilibrium:\n\n$$ D + R \\rightleftharpoons DR $$\n\nThe dissociation constant, $K_d$, is defined at equilibrium as:\n\n$$ K_d = \\frac{[D][R]}{[DR]} $$\n\nThe total number of receptors, $R_{tot}$, is the sum of free and bound receptors: $R_{tot} = [R] + [DR]$. The fractional occupancy of the receptors is the ratio of bound receptors to the total number of receptors, $[DR]/R_{tot}$. By substituting $[R] = R_{tot} - [DR]$ into the $K_d$ expression and rearranging, we can express the fractional occupancy as a function of the drug concentration $[D]$:\n\n$$ \\text{Fractional Occupancy} = \\frac{[DR]}{R_{tot}} = \\frac{[D]}{K_d + [D]} $$\n\nA fundamental assumption in this model is that the observed pharmacological effect, $E$, is directly proportional to the fractional receptor occupancy. The maximum possible effect, $E_{\\max}$, occurs when all receptors are occupied (i.e., at saturating drug concentrations). Thus:\n\n$$ E = E_{\\max} \\cdot (\\text{Fractional Occupancy}) $$\n\nSubstituting the expression for fractional occupancy, we arrive at the standard saturable Emax model:\n\n$$ E(D) = \\frac{E_{\\max} \\cdot D}{EC_{50} + D} $$\n\nIn this equation:\n*   $E(D)$ is the effect at a given dose $D$. In this problem, the effect is the change in heart rate, $\\Delta HR = HR_{\\text{baseline}} - HR_{\\text{post}}$.\n*   $D$ is the dose of the drug, in milligrams.\n*   $E_{\\max}$ is the maximum possible effect (maximum $\\Delta HR$), in beats per minute.\n*   $EC_{50}$ is the dose that produces $50\\%$ of the maximum effect. It is a measure of the drug's potency and is mathematically equivalent to the dissociation constant $K_d$ under these assumptions.\n\n**2. Parameter Estimation via Non-Linear Least Squares**\n\nThe parameters $E_{\\max}$ and $EC_{50}$ are unknown and must be estimated from the experimental data. This is achieved by fitting the Emax model to the observed $(\\text{Dose}, \\Delta HR)$ pairs. The method of choice is non-linear least squares (NLLS). NLLS finds the parameter values ($\\hat{E}_{\\max}, \\hat{EC}_{50}$) that minimize the sum of the squared differences (residuals) between the observed effect and the effect predicted by the model:\n\n$$ \\text{min} \\sum_{i=1}^{n} \\left( \\Delta HR_i - \\frac{\\hat{E}_{\\max} \\cdot \\text{Dose}_i}{\\hat{EC}_{50} + \\text{Dose}_i} \\right)^2 $$\n\nwhere the sum is over all $n$ data points for a given genotype. This minimization problem is solved numerically using an iterative optimization algorithm. The `scipy.optimize.curve_fit` function in Python, which typically uses the Levenberg-Marquardt algorithm, is well-suited for this task.\n\n**3. Implementation Strategy**\n\nThe overall algorithm proceeds as follows for each test case:\n1.  For each genotype (A and B), the observed effect data, $\\Delta HR$, are first calculated by subtracting the post-dose heart rate from the baseline heart rate for each observation.\n2.  The Emax model function, $f(D; E_{\\max}, EC_{50})$, is defined.\n3.  The `scipy.optimize.curve_fit` function is called to perform the NLLS fit. The inputs are the model function, the vector of doses (independent variable), and the vector of calculated $\\Delta HR$ values (dependent variable).\n4.  Crucially, the pharmacologically plausible constraints, $E_{\\max} \\in [0, 100]$ bpm and $EC_{50} \\in [10^{-3}, 200]$ mg, are supplied to the optimizer as bounds. This prevents the algorithm from converging to physically meaningless parameter values.\n5.  This procedure is performed independently for Genotype A and Genotype B, yielding a separate set of $(\\hat{E}_{\\max}, \\hat{EC}_{50})$ estimates for each.\n6.  The final estimated parameters are rounded to two decimal places as required. The results for all test cases are then aggregated into the specified final output format.", "answer": "```python\n# The complete and runnable Python 3 code goes here.\n# Imports must adhere to the specified execution environment.\nimport numpy as np\nfrom scipy.optimize import curve_fit\n\ndef solve():\n    \"\"\"\n    Fits a saturable dose-effect model (Emax model) to pharmacodynamic data\n    to estimate genotype-specific Emax and EC50 parameters.\n    \"\"\"\n\n    # Define the test cases from the problem statement.\n    test_cases = [\n        # Test Case 1\n        {\n            \"Genotype A\": {\n                \"Dose\": np.array([0, 2, 2, 5, 5, 10, 10, 25, 25]),\n                \"Baseline HR\": np.array([80, 82, 78, 81, 79, 83, 77, 84, 80]),\n                \"Post-dose HR\": np.array([80, 73.729, 69.329, 65.8, 64.5, 63.0, 57.4, 58.7, 55.2])\n            },\n            \"Genotype B\": {\n                \"Dose\": np.array([0, 2, 2, 5, 5, 10, 10, 25, 25]),\n                \"Baseline HR\": np.array([78, 80, 82, 79, 83, 84, 76, 85, 81]),\n                \"Post-dose HR\": np.array([78, 77.747, 79.447, 74.3, 77.9, 76.2, 68.0, 72.1, 69.0])\n            }\n        },\n        # Test Case 2\n        {\n            \"Genotype A\": {\n                \"Dose\": np.array([0, 20, 20, 40, 40, 80, 80]),\n                \"Baseline HR\": np.array([88, 90, 86, 87, 89, 90, 85]),\n                \"Post-dose HR\": np.array([88, 59.765, 55.465, 54.742, 55.942, 56.266, 51.366])\n            },\n            \"Genotype B\": {\n                \"Dose\": np.array([0, 20, 20, 40, 40, 80, 80]),\n                \"Baseline HR\": np.array([92, 91, 90, 88, 89, 90, 87]),\n                \"Post-dose HR\": np.array([92, 65.9, 65.2, 58.633, 59.833, 58.482, 55.082])\n            }\n        },\n        # Test Case 3\n        {\n            \"Genotype A\": {\n                \"Dose\": np.array([0, 1, 1, 2, 2, 4, 4, 8, 8]),\n                \"Baseline HR\": np.array([80, 82, 78, 81, 79, 83, 77, 84, 80]),\n                \"Post-dose HR\": np.array([80, 81.61, 77.31, 80.038, 78.238, 81.048, 75.148, 80.752, 76.252])\n            },\n            \"Genotype B\": {\n                \"Dose\": np.array([0, 1, 1, 2, 2, 4, 4, 8, 8]),\n                \"Baseline HR\": np.array([81, 80, 82, 79, 83, 84, 76, 85, 81]),\n                \"Post-dose HR\": np.array([81, 75.733, 77.833, 72.057, 75.657, 72.889, 65.189, 69.215, 65.715])\n            }\n        }\n    ]\n\n    def emax_model(dose, Emax, EC50):\n        \"\"\"Saturable Emax model for dose-response relationship.\"\"\"\n        # Add a small epsilon to EC50 + dose to avoid division by zero if dose=-EC50, though not expected here\n        return (Emax * dose) / (EC50 + dose + 1e-9)\n\n    all_results = []\n    \n    # Define parameter bounds as specified\n    bounds = ([0, 1e-3], [100, 200])\n    # Define a robust initial guess\n    p0 = [20, 10]\n\n    for case_data in test_cases:\n        case_results = []\n        genotypes = [\"Genotype A\", \"Genotype B\"]\n        \n        for genotype in genotypes:\n            data = case_data[genotype]\n            dose = data[\"Dose\"]\n            baseline_hr = data[\"Baseline HR\"]\n            post_dose_hr = data[\"Post-dose HR\"]\n            \n            # Calculate the effect (change in heart rate)\n            delta_hr = baseline_hr - post_dose_hr\n            \n            # Perform non-linear least squares fitting\n            try:\n                popt, _ = curve_fit(emax_model, dose, delta_hr, bounds=bounds, p0=p0, maxfev=5000)\n                Emax_fit, EC50_fit = popt\n            except RuntimeError:\n                # Fallback in case of fitting failure, though not expected with this data\n                Emax_fit, EC50_fit = np.nan, np.nan\n\n            # Append rounded results to the list for the current case\n            case_results.append(round(Emax_fit, 2))\n            case_results.append(round(EC50_fit, 2))\n            \n        all_results.append(case_results)\n\n    # Final print statement in the exact required format.\n    print(all_results)\n\nsolve()\n```", "id": "5042251"}]}